93 related articles for article (PubMed ID: 23623559)
1. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
Braulke F; Jung K; Schanz J; Götze K; Müller-Thomas C; Platzbecker U; Germing U; Brümmendorf TH; Bug G; Ottmann O; Giagounidis AA; Stadler M; Hofmann WK; Schafhausen P; Lübbert M; Schlenk RF; Blau IW; Ganster C; Pfeiffer S; Shirneshan K; Metz M; Detken S; Seraphin J; Jentsch-Ullrich K; Böhme A; Schmidt B; Trümper L; Haase D
Leuk Res; 2013 Aug; 37(8):900-6. PubMed ID: 23623559
[TBL] [Abstract][Full Text] [Related]
2. FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients.
Braulke F; Schanz J; Jung K; Shirneshan K; Schulte K; Schuetze C; Steffens R; Trümper L; Haase D
Leuk Res; 2010 Oct; 34(10):1296-301. PubMed ID: 20226527
[TBL] [Abstract][Full Text] [Related]
3. Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.
Braulke F; Müller-Thomas C; Götze K; Platzbecker U; Germing U; Hofmann WK; Giagounidis AA; Lübbert M; Greenberg PL; Bennett JM; Solé F; Slovak ML; Ohyashiki K; Le Beau MM; Tüchler H; Pfeilstöcker M; Hildebrandt B; Aul C; Stauder R; Valent P; Fonatsch C; Bacher U; Trümper L; Haase D; Schanz J
Genes Chromosomes Cancer; 2015 Dec; 54(12):809-17. PubMed ID: 26355708
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
Braulke F; Schulz X; Germing U; Schuler E; Platzbecker U; Nolte F; Hofmann WK; Giagounidis A; Götze K; Lübbert M; Schlenk RF; Schanz J; Bacher U; Ganser A; Büsche G; Letsch A; Schafhausen P; Bug G; Brümmendorf TH; Haas R; Trümper L; Shirneshan K; Haase D
Ann Hematol; 2017 Jun; 96(6):887-894. PubMed ID: 28374162
[TBL] [Abstract][Full Text] [Related]
5. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.
Braulke F; Platzbecker U; Müller-Thomas C; Götze K; Germing U; Brümmendorf TH; Nolte F; Hofmann WK; Giagounidis AA; Lübbert M; Greenberg PL; Bennett JM; Solé F; Mallo M; Slovak ML; Ohyashiki K; Le Beau MM; Tüchler H; Pfeilstöcker M; Nösslinger T; Hildebrandt B; Shirneshan K; Aul C; Stauder R; Sperr WR; Valent P; Fonatsch C; Trümper L; Haase D; Schanz J
Haematologica; 2015 Feb; 100(2):205-13. PubMed ID: 25344522
[TBL] [Abstract][Full Text] [Related]
6. [Study on the role of fluorescence in situ hybridization in cytogenetic evaluation of myelodysplastic syndrome].
Qu SQ; Xu ZF; Li CW; Liu XP; Qin TJ; Zhang Y; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):839-42. PubMed ID: 23384907
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of complex chromosomal aberrations in patients with myelodysplastic syndromes using multiplex fluorescence in situ hybridization combined with whole chromosome painting].
Chen LJ; Li JY; Xiao B; Zhu Y; Liu Q; Pan JL; Qiu HR; Fan L; Zhang SJ; Lu RN; Xu W; Xue YQ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):635-9. PubMed ID: 18067073
[TBL] [Abstract][Full Text] [Related]
8. Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?
Costa D; Valera S; Carrió A; Arias A; Muñoz C; Rozman M; Belkaid M; Coutinho R; Nomdedeu B; Campo E
Leuk Res; 2010 Nov; 34(11):1437-41. PubMed ID: 20226525
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of classic cytogenetic testing compared to fluorescence in situ hybridization in genetic diagnosis of 58 patients with myelodysplastic syndromes.
Skonieczka K; Duszeńko E; Wyrowińska E; Haus O
Pol Arch Med Wewn; 2009 Jun; 119(6):366-72. PubMed ID: 19694218
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS/sAML: A monocentric real-world experience.
Braulke F; Schweighöfer A; Schanz J; Shirneshan K; Ganster C; Pollock-Kopp B; Leha A; Haase D
Leuk Res; 2023 Jan; 124():106996. PubMed ID: 36538857
[TBL] [Abstract][Full Text] [Related]
11. Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: a multicenter prospective study of 2302 patients in China.
Lai YY; Huang XJ; Li J; Zou P; Xu ZF; Sun H; Shao ZH; Zhou DB; Chen FP; Liu ZG; Zhu HL; Wu DP; Wang C; Zhang Y; Li Y; Hou M; Du X; Wang X; Li W; Lai YR; Zhou J; Zhou YH; Fang MY; Qiu L; Wang XM; Zhang GS; Jiang M; Liang YM; Zhang LS; Chen XQ; Bai H; Lin JY
Leuk Res; 2015 May; 39(5):530-5. PubMed ID: 25823643
[TBL] [Abstract][Full Text] [Related]
12. Conventional and molecular cytogenetic features of myelodysplastic syndrome in China.
Chen L; Li J; Zhu Y; Qiu H; Pan J; Wang R; Qian S; Xu W; Xue Y
Exp Oncol; 2007 Dec; 29(4):299-303. PubMed ID: 18199987
[TBL] [Abstract][Full Text] [Related]
13. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?
Cherry AM; Slovak ML; Campbell LJ; Chun K; Eclache V; Haase D; Haferlach C; Hildebrandt B; Iqbal AM; Jhanwar SC; Ohyashiki K; Sole F; Vandenberghe P; VanDyke DL; Zhang Y; Dewald GW
Leuk Res; 2012 Jul; 36(7):832-40. PubMed ID: 22537394
[TBL] [Abstract][Full Text] [Related]
14. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells.
Rigolin GM; Porta MD; Ciccone M; Bugli AM; Bragotti LZ; Mauro E; Fraulini C; Rossi AR; Bardi A; Cuneo A; Castoldi G
Br J Haematol; 2004 Aug; 126(4):501-7. PubMed ID: 15287942
[TBL] [Abstract][Full Text] [Related]
15. FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes?
Yang W; Stotler B; Sevilla DW; Emmons FN; Murty VV; Alobeid B; Bhagat G
Leuk Res; 2010 Apr; 34(4):420-5. PubMed ID: 19800120
[TBL] [Abstract][Full Text] [Related]
16. Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology.
Bernell P; Jacobsson B; Nordgren A; Hast R
Leukemia; 1996 Apr; 10(4):662-8. PubMed ID: 8618444
[TBL] [Abstract][Full Text] [Related]
17. Quantity of clonal cells detected by conventional cytogenetic analysis correlates with bone marrow blasts and survival in myelodysplastic syndromes.
Kim M; Chung S; See CJ; Yoon SS; Kim BK; Kim HK; Lee DS
Leuk Res; 2012 Feb; 36(2):163-8. PubMed ID: 21920602
[TBL] [Abstract][Full Text] [Related]
18. [Karyotype studies of patients with a myelodysplastic syndrome].
Salamanchuk ZIa; Masliak ZV; Lozyns'ka MR; Vyhovs'ka IaI; Lohins'kyĭ VIe; Male P
Tsitol Genet; 1998; 32(1):43-8. PubMed ID: 9695251
[TBL] [Abstract][Full Text] [Related]
19. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
Blau O; Hofmann WK; Baldus CD; Thiel G; Serbent V; Schümann E; Thiel E; Blau IW
Exp Hematol; 2007 Feb; 35(2):221-9. PubMed ID: 17258071
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic and comparative genomic hybridization study of Indian myelodysplastic syndromes.
Kawankar N; Jijina F; Ghosh K; Vundinti BR
Cancer Epidemiol; 2011 Aug; 35(4):e1-5. PubMed ID: 21193364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
